rsv polymerase

BTA-9881 is a novel RSV fusion inhibitor with oral activity and antiviral activity for the study of respiratory syncytial virus infections.

Totrombopag (SB559448) is a candidate compound for action on RSV polymerase.

ALS-8112 (ALS 008112) is a selective and potent inhibitor of respiratory syncytial virus (RSV) polymerase with an IC50 value of 0.02 μM. ALS-8112 exhibits antiviral activity and inhibits the RNA polymerase activity of the RSV L-P protein complex through RNA chain termination. virus infections.

Lumicitabine (ALS-008176) is an RSV polymerase inhibitor.

Ribavirin (Tribavirin) is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses.

PC786 is a potent and selective non-nucleoside RSV L-protein polymerase inhibitor for inhalation therapy of RSV infections, with antiviral activity against RSV-A (IC50=0.09-0.71 nM) and RSV-B (IC 50=1.3-50.6 nM), and the ability to inhibit RSV RNA-dependent RNA polymerase in HEp-2 cells ( RdRp).

GHP-88309 is an orally active broad-spectrum anti-paramyxovirus agent that targets viral polymerase and interrupts viral RNA synthesis. GHP-88309 inhibits respiratory syncytial virus (RSV), measles virus (MeV), and canine distemper virus (CDV), with EC50 values ranging from 0.06 to 1.2 μM. In mouse models, GHP-88309 demonstrates significant anti-infective activity. The antiviral profile of GHP-88309 supports the application of GHP-88309 in virology research, viral replication studies, antiviral agent development, and investigations of paramyxovirus biology.

RSVL-protein-6 (Compound 19a) is an inhibitor of respiratory syncytial virus (RSV) polymerase, with an IC50 of 13 nM in an SPA primer extension-based enzymatic assay. It is capable of inhibiting RSV replication in HeLa cells.

ALS-8112-TP is the 5'-triphosphate metabolite of ALS-8112. This compound acts as a potent, selective, and competitive inhibitor of respiratory syncytial virus (RSV) RNA polymerase, demonstrating selectivity over host or unrelated viral polymerases, such as the hepatitis C virus (HCV). It is efficiently recognized by the recombinant RSV polymerase complex, resulting in the termination of RNA synthesis. ALS-8112-TP is applicable in the research of RSV infections.

Ribavirin-13C5 is intended for use as an internal standard for the quantification of ribavirin by GC- or LC-MS. Ribavirin (T0684) is an antiviral guanosine nucleoside analog.1,2Upon entry into cells, ribavirin is metabolized to an active triphosphate form that induces viral RNA chain termination and inhibits viral polymerases. It reduces replication in a panel of seven RNA and four DNA viruses in Vero cells (EC50s = 2-95 μg/ml).3Ribavirin also reduces replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Vero cells (EC50= 109.5 μM).4Aerosol administration of ribavirin (30 mg/kg) reduces mortality in a mouse model of influenza A infection.5Formulations containing ribavirin have been used in the treatment of respiratory syncytial virus (RSV), hepatitis C virus (HCV), and viral hemorrhagic fevers.

AVG-233 is an orally available RNA-dependent RNA polymerase (RdRp) inhibitor with antiviral activity that blocks respiratory syncytial virus and SARS-CoV-2 replication.AVG-233 is used in the study of respiratory syncytial virus infections.

RSV L-protein-IN-2 (Compound A) is a noncompetitive inhibitor of the RSV polymerase with an IC50 of 4.5 μM and demonstrates antiviral activity against long RSV strains with an EC50 of 1.3 μM [1].

RSV L-protein-IN-3 is an inhibitor of wild-type RSV polymerase with an IC50 of 10.4 μM and an EC50 of 2.1 μM (against RSV) and exhibits lower cytotoxicity than the clinical agent Ribavirin [1].

RSV L-protein-IN-4 (Compound C) is a noncompetitive inhibitor of the RSV polymerase, exhibiting an IC50 of 0.88 μM and demonstrating potent antiviral activity against RSV strains with an EC50 of 0.25 μM [1].

RSV L-protein-IN-5 (Compound E) serves as a potent inhibitor of the Respiratory Syncytial Virus (RSV), with an EC50 value of 0.1 μM. It targets RSV polymerase with an IC50 of 0.66 μM and impedes RSV mRNA synthesis through the inhibition of transcript guanylation. The compound demonstrates moderate cytotoxicity, with a CC50 of 10.7 μM in HEp-2 cells, and effectively reduces viral titers in mouse models of RSV infection [1].

JNJ-8003 is a potent inhibitor of RSV Polymerase, impeding early RNA transcription and replication by inhibiting nucleotide polymerization [1].

JNJ-7184 is a non-nucleoside inhibitor of the RSV-Large (L) polymerase, with pEC50 and pCC50 values of 7.86 and 4.29, respectively, in Hela cells. It inhibits the initiation or early elongation phases, thereby preventing RSV replication and transcription.

GS-646089 is a broad-spectrum antiviral nucleoside analog that exhibits significant inhibitory activity against respiratory syncytial virus (RSV), human metapneumovirus (hMPV), rhinovirus (enterovirus), and enterovirus. It targets RNA-dependent RNA polymerase (RdRp) with an IC50 of 43-46 nM. Within cells, GS-646089 is converted into a triphosphate metabolite, competitively incorporating with ATP into nascent RNA chains to act as an immediate chain terminator, thereby blocking viral replication. GS-646089 is the parent compound of the double prodrug GS-7682 and has been utilized in studies of acute respiratory virus infections and related pathogens.